NasdaqGM:CRSPBiotechs
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story
CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution.
The company highlights a threefold increase in projected patient initiations for 2025, signaling growing real world adoption of CASGEVY.
Alongside CASGEVY traction, CRISPR Therapeutics advances new gene editing programs and partnerships, expanding its clinical pipeline.
CRISPR Therapeutics, trading at $48.75, is moving further into a...